UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...
Despite the notable advancements in cancer pharmacotherapy, such as chemotherapy, targeted therapy, and immunotherapy, which have significantly improved patient survival rates, managing the associated ...